98%
921
2 minutes
20
Colorectal cancer remains a major global health challenge, emphasizing the need for advanced diagnostic tools that enable early and accurate detection. Photoacoustic (PA) spectroscopy, a hybrid technique combining optical absorption with acoustic resolution, is emerging as a powerful tool in cancer diagnostics. It detects biochemical changes in biomolecules within the tumor microenvironment, aiding early identification of malignancies. Integration with modalities, such as ultrasound (US), photoacoustic microscopy (PAM), and nanoparticle-enhanced imaging, enables detailed mapping of tissue structure, vascularity, and molecular markers. When combined with endoscopy and machine learning (ML) for data analysis, PA technology offers real-time, minimally invasive, and highly accurate detection of colorectal tumors. This approach supports tumor classification, therapy monitoring, and detecting features like hypoxia and tumor-associated bacteria. Recent studies integrating machine learning with PA imaging have demonstrated high diagnostic accuracy, achieving area under the curve (AUC) values up to 0.96 and classification accuracies exceeding 89%, highlighting its potential for precise, noninvasive colorectal cancer detection. Continued advancements in nanoparticle design, molecular targeting, and ML analytics position PA as a key tool for personalized colorectal cancer management.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12264766 | PMC |
http://dx.doi.org/10.1021/acsbiomaterials.5c00918 | DOI Listing |
Cancer Epidemiol Biomarkers Prev
September 2025
Brigham and Women's Hospital, Boston, MA, United States.
Background: Colorectal cancer (CRC) risk models routinely adjust for endoscopic screening because of a) possible confounding with other risk factors and b) possible alteration of natural history of the disease due to adenoma detection and removal.
Methods: In this study, we defined a subject as screen-covered (SC) if a colonoscopy was performed in the past 10 years, and not screen-covered (NSC) otherwise. We created CRC risk models separately for SC and NSC subjects (HRSC, HRNSC) and then obtained a screening-coverage adjusted HR estimate (HRfull) based on a weighted average of ln(HRSC) and ln(HRNSC) with weight equal to the proportion of SC person-time in the NHS population.
JACC Case Rep
September 2025
Department of Cardiovascular Surgery, Nagoya Heart Center, Nagoya, Japan.
Background: Capecitabine, an oral prodrug of 5-fluorouracil, is widely used for gastrointestinal malignancies. While its coronary toxicity is well documented, large-vessel complications such as aortic dissection are rarely reported.
Case Summary: We present a 65-year-old man with colorectal cancer who developed Stanford type A aortic dissection 3 days after initiating adjuvant capecitabine therapy.
Br J Surg
September 2025
Department of Digestive Surgery, CARPEM Comprehensive Cancer Centre, Georges-Pompidou European Hospital, AP-HP, Université Paris-Cité, Paris, France.
Rep Pract Oncol Radiother
August 2025
Cardiac Surgery and Transplantology Department, Poznan University of Medical Sciences, Poznan, Poland.
Background: The rising burden of colorectal cancer with a high prevalence of advanced stages of new-onset is reported worldwide. While applied, chemotherapy can extend patients' survival, and proper tailoring is paramount. Based on computed tomography results, the study aimed to point out potential prognostic factors of complete or partial response to the initial three months of chemotherapy in palliative colorectal (CRC) cancer.
View Article and Find Full Text PDFFront Chem
August 2025
Guangzhou Key Laboratory of Formula-Pattern Research Center, School of Traditional Chinese Medicine, The Fifth Affiliated Hospital of Jinan University (Heyuan Shenhe People's Hospital), Jinan University, Guangzhou, China.
Introduction: Colorectal cancer (CRC) is a prevalent malignant tumor of the digestive tract. The FOLFOX regimen (oxaliplatin + calcium folinate + 5-fluorouracil) serves as the primary treatment for advanced CRC clinically, yet its application is significantly limited by substantial toxic side effects. Erianin, a natural compound from Chinese medicine Lindl, demonstrates significant potential in both tumor growth inhibition and chemotherapy toxicity reduction.
View Article and Find Full Text PDF